112 related articles for article (PubMed ID: 38749381)
21. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
22. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
[TBL] [Abstract][Full Text] [Related]
23. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
25. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F; Neha K; Chauhan G
Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
[TBL] [Abstract][Full Text] [Related]
26. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
28. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
Nishio M; Ohe Y; Ohashi K; Toyozawa R; Satouchi M; Sekine N; Mori J; Enatsu S; Goto K
Gan To Kagaku Ryoho; 2022 Jun; 49(6):669-675. PubMed ID: 35799394
[TBL] [Abstract][Full Text] [Related]
30. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
31. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S; Shaw AT; Besse B; Felip E; Solomon BJ; Soo RA; Bearz A; Gadgeel SM; Lin CC; Kao S; Seto T; Masters ET; Abbattista A; Clancy JS; Thurm H; Reisman A; Peltz G; Ross Camidge D
Lung Cancer; 2020 Jun; 144():10-19. PubMed ID: 32344248
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of selpercatinib in Chinese patients with advanced
Zheng X; Ji Q; Sun Y; Ge M; Zhang B; Cheng Y; Lei S; Shi F; Guo Y; Li L; Chen L; Shao J; Zhang W; Gao M
Ther Adv Med Oncol; 2022; 14():17588359221119318. PubMed ID: 36062046
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract][Full Text] [Related]
34. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
35. Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC.
Cancer Discov; 2023 Dec; 13(12):OF8. PubMed ID: 37874126
[TBL] [Abstract][Full Text] [Related]
36. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A; Gambale C; Cappagli V; Bottici V; Rossi P; Caciagli M; Papini P; Taddei D; Ortori S; Gabbrielli L; Celi A; Materazzi G; Elisei R; Matrone A
Eur J Endocrinol; 2022 Dec; 187(6):905-915. PubMed ID: 36314655
[TBL] [Abstract][Full Text] [Related]
37. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.
Elisei R; Ciampi R; Matrone A; Prete A; Gambale C; Ramone T; Simeakis G; Materazzi G; Torregrossa L; Ugolini C; Romei C
J Clin Endocrinol Metab; 2022 Jul; 107(8):2195-2202. PubMed ID: 35616103
[TBL] [Abstract][Full Text] [Related]
38. Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.
Darabi S; Adeyelu T; Elliott A; Sukari A; Hodges K; Abdulla F; Zuazo CE; Wise-Draper T; Wang T; Demeure MJ
J Am Coll Surg; 2024 Jul; 239(1):50-60. PubMed ID: 38651727
[TBL] [Abstract][Full Text] [Related]
39. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
40. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
